Spyros Pournaras

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Belén Gutiérrez‐Gutiérrez, Elena Salamanca, Marina de Cueto et al. · The Lancet Infectious Diseases · 2017 · 521 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment

Olympia Zarkotou, Spyros Pournaras, Paraskevi Tselioti et al. · Clinical Microbiology and Infection · 2011 · 441 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Defining Fractional Inhibitory Concentration Index Cutoffs for Additive Interactions Based on Self-Drug Additive Combinations, Monte Carlo Simulation Analysis, and <i>In Vitro</i> - <i>In Vivo</i> Correlation Data for Antifungal Drug Combinations against <i>Aspergillus fumigatus</i>

Joseph Meletiadis, Spyros Pournaras, Emmanuel Roilides et al. · Antimicrobial Agents and Chemotherapy · 2009 · 332 citations · Full text

Medicine, Pharmacology, Biopharmaceutics +16

Outbreak of Infections Caused by <i>Pseudomonas aeruginosa</i> Producing VIM-1 Carbapenemase in Greece

Athanasios Tsakris, Spyros Pournaras, Neil Woodford et al. · Journal of Clinical Microbiology · 2000 · 261 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

A simple phenotypic method for the differentiation of metallo- -lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates

Athanasios Tsakris, Aggeliki Poulou, Spyros Pournaras et al. · Journal of Antimicrobial Chemotherapy · 2010 · 246 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17